More exciting news for migraine sufferers! On April 17th, 2023, FDA approved a novel medication rizatriptan orally disintegrating film (Rizafilm). This is the first rizatriptan oral disintegrating film to achieve approval in the E.U. and U.S.. Rizafilm is the first oral thin film using IntelGenx proprietary drug delivery technology, VersaFilm, for the acute treatment of migraine with or without aura. It is an orally disintegrating film, without need for water, providing exceptional convenience for migraine patients experiencing nausea or trouble swallowing. In clinical studies Rizafilm was shown to be bioequivalent to Maxalt-MLT (Merck & Co.). To learn more follow the link below: https://www.neurologylive.com/view/fda-approves-intelgenx-and-gensco-s-rizatriptan-for-acute-migraine-treatment
